ADMA Biologics Inc (ADMA) Stock Price Up 11.3%

ADMA Biologics Inc (NASDAQ:ADMA) rose 11.3% during mid-day trading on Thursday . The stock traded as high as $3.48 and last traded at $3.06. Approximately 703,300 shares traded hands during trading, an increase of 1,134% from the average daily volume of 57,012 shares. The stock had previously closed at $2.75.

A number of research firms have recently weighed in on ADMA. Raymond James Financial, Inc. upgraded shares of ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a research report on Tuesday. ValuEngine downgraded shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.

The company has a debt-to-equity ratio of 2.26, a quick ratio of 1.35 and a current ratio of 2.36.

In other ADMA Biologics news, insider Adam S. Grossman purchased 485,000 shares of the company’s stock in a transaction dated Thursday, November 9th. The stock was bought at an average cost of $2.15 per share, for a total transaction of $1,042,750.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Eric I. Richman purchased 25,000 shares of the company’s stock in a transaction dated Thursday, November 9th. The stock was acquired at an average price of $2.15 per share, with a total value of $53,750.00. Following the completion of the transaction, the director now owns 31,300 shares of the company’s stock, valued at approximately $67,295. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 526,500 shares of company stock valued at $1,131,975. 60.44% of the stock is owned by company insiders.

An institutional investor recently raised its position in ADMA Biologics stock. Iguana Healthcare Management LLC increased its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 276.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 565,000 shares of the biotechnology company’s stock after buying an additional 415,000 shares during the period. Iguana Healthcare Management LLC owned 2.19% of ADMA Biologics worth $1,740,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 34.55% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at

ADMA Biologics Company Profile

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply